Associated Papers
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
Cuevas-Navarro A et al.
Science Advances, 2023
Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.
Berger AH et al.
Oncogene, 2022
Noonan syndrome caused by RIT1 gene mutation: A case report and literature review.
Zha P et al.
Frontiers in Pediatrics, 2022
The RAS GTPase RIT1 compromises mitotic fidelity through spindle assembly checkpoint suppression.
Cuevas-Navarro A et al.
Current Biology : Cb, 2021
The molecular functions of RIT1 and its contribution to human disease.
Van R et al.
The Biochemical Journal, 2020
RIT1 oncoproteins escape LZTR1-mediated proteolysis.
Castel P et al.
Science (new York, N.y.), 2019
RIT1 controls actin dynamics via complex formation with RAC1/CDC42 and PAK1.
Meyer Zum Büschenfelde U et al.
Plos Genetics, 2018
Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1).
Fang Z et al.
The Journal of Biological Chemistry, 2016
Mutations in RIT1 cause Noonan syndrome - additional functional evidence and expanding the clinical phenotype.
Koenighofer M et al.
Clinical Genetics, 2016
Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.
Yaoita M et al.
Human Genetics, 2016
RASopathies: unraveling mechanisms with animal models.
Jindal GA et al.
Disease Models & Mechanisms, 2015
26203125 (PubMed )
Supplement: supp_8.8.769_DMM020339supp.pdf
Next-generation sequencing identifies rare variants associated with Noonan syndrome.
Chen PC et al.
Proceedings of the National Academy of Sciences of the United States of America, 2014
Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.
Gómez-Seguí I et al.
Leukemia, 2013
Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
Aoki Y et al.
American Journal of Human Genetics, 2013
Select a paper to view details